← Leaderboards
Gregory A. Grabowski
Children'S Hospital Med Ctr (Cincinnati)
$10,832,896
Attributed
$11,040,124
Total exposure
14
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–13$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$11,040,124 · 14
By mechanism
R01$9,614,426 · 5
R21$835,064 · 2
U54$420,651 · 1
M01$169,983 · 6
Top collaborators
- Dao Pan1 shared
Most similar at Children'S Hospital Med Ctr (Cincinnati)
Same institution · by research overlap
- Xiaoyang Qi$7,187,712
Others in their field
Top investigators on “Variant”
- Richard A Gibbs · Baylor College Of Medicine$367,607,426
- Richard K. Wilson · Washington University$295,336,569
- Stacey Gabriel · Massachusetts Institute Of Technology$169,231,712
- David Heimbrook · Leidos Biomedical Research, Inc.$125,120,179
- Heidi L Rehm · Broad Institute, Inc.$96,250,516
- Margaret A Pericak-Vance · Doheny Eye Institute$83,999,609
Research focus
VariantEnzyme ActivityIn VivoEnzymesGlycosphingolipidsGaucher DiseaseMouse ModelMutationPrototypeCentral Nervous System DiseasesAcidsLiverGlucosylceramidesTraffickingGlucosidaseInhibitor/AntagonistOrganExhibitsMutantDisease ProgressionResponseBiochemicalPathologic ProcessesMolecular Chaperones
Grant awards (50)
Gaucher disease:Treatment of neurodegenerative disease$414,457
R01 · FY2013 · NS
Epidemiology and Natural History of Wolman and Cholesteryl Ester Stor (Grabowski)$78,540
U54 · FY2013 · NS · contact PI
Epidemiology and Natural History of Wolman and Cholesteryl Ester Stor (Grabowski)$78,998
U54 · FY2012 · NS · contact PI
Studies of Gaucher Disease: A Prototype Lipidosis$425,819
R01 · FY2011 · DK · contact PI
Epidemiology and Natural History of Wolman and Cholesteryl Ester Stor (Grabowski)$76,892
U54 · FY2011 · NS · contact PI
Studies of Gaucher Disease: A Prototype Lipidosis$9,500
R01 · FY2011 · DK · contact PI
Studies of Gaucher Disease: A Prototype Lipidosis$515,249
R01 · FY2010 · DK · contact PI
Therapy of Neuronopathic Gaucher Disease$259,875
R21 · FY2010 · HD · contact PI
Therapy of Gaucher Disease: In Vivo Enhancement of Residual Mutant Activity$222,176
R21 · FY2010 · NS · contact PI
Studies of Gaucher Disease: A Prototype Lipidosis$101,500
R01 · FY2010 · DK · contact PI
Epidemiology and Natural History of Wolman and Cholesteryl Ester Stor (Grabowski)$93,276
U54 · FY2010 · NS · contact PI
Studies of Gaucher Disease: A Prototype Lipidosis$10,500
R01 · FY2010 · DK · contact PI
Therapy of Neuronopathic Gaucher Disease$6,388
R21 · FY2010 · HD · contact PI
Studies of Gaucher Disease: A Prototype Lipidosis$425,748
R01 · FY2009 · DK · contact PI
Therapy of Gaucher Disease: In Vivo Enhancement of Residual Mutant Activity$190,325
R21 · FY2009 · NS · contact PI
Therapy of Neuronopathic Gaucher Disease$150,000
R21 · FY2009 · HD · contact PI
Grabowski$92,945
U54 · FY2009 · NS · contact PI
Studies of Gaucher Disease: A Prototype Lipidosis$84,000
R01 · FY2009 · DK · contact PI
Studies of Gaucher Disease: A Prototype Lipidosis$7,500
R01 · FY2009 · DK · contact PI
Therapy of Neuronopathic Gaucher Disease$6,300
R21 · FY2009 · HD · contact PI
Studies of Gaucher Disease: A Prototype Lipidosis$415,353
R01 · FY2008 · DK · contact PI
Studies of Prosaposin's Physiologic Role$428,302
R01 · FY2007 · NS · contact PI
Studies of Gaucher Disease: A Prototype Lipidosis$413,531
R01 · FY2007 · DK · contact PI
Use of Hammerhead Ribozymes in Murine Models of Ol$401,541
R01 · FY2007 · AR · contact PI
GAUCHER DISEASE STUDY$11,142
M01 · FY2007 · RR · contact PI
Studies of Prosaposin's Physiologic Role$429,029
R01 · FY2006 · NS · contact PI
Use of Hammerhead Ribozymes in Murine Models of Ol$403,251
R01 · FY2006 · AR · contact PI
GAUCHER DISEASE STUDY$17,722
M01 · FY2006 · RR · contact PI
Studies of Prosaposin's Physiologic Role$415,795
R01 · FY2005 · NS
Studies of Gaucher Disease: A Prototype Lipidosis$371,353
R01 · FY2005 · DK
GAUCHER DISEASE STUDY$10,604
M01 · FY2005 · RR
Studies of Prosaposin's Physiologic Role$415,795
R01 · FY2004 · NS
Studies of Gaucher Disease: A Prototype Lipidosis$362,273
R01 · FY2004 · DK
INBORN ERRORS OF SPHINGOLIPID CATABOLISM$248,856
R01 · FY2004 · NS
Gaucher Disease Study$16,355
M01 · FY2004 · RR
Studies of Prosaposin's Physiologic Role$430,216
R01 · FY2003 · NS
Studies of Gaucher Disease: A Prototype Lipidosis$353,460
R01 · FY2003 · DK
INBORN ERRORS OF SPHINGOLIPID CATABOLISM$242,319
R01 · FY2003 · NS
Studies of Gaucher Disease: A Prototype Lipidosis$355,410
R01 · FY2002 · DK
INBORN ERRORS OF SPHINGOLIPID CATABOLISM$231,191
R01 · FY2002 · NS
Studies of Gaucher Disease: A Prototype Lipidosis$375,601
R01 · FY2001 · DK
PROSAPOSINS PHYSIOLOGIC ROLE$266,234
R01 · FY2001 · NS
INBORN ERRORS OF SPHINGOLIPID CATABOLISM$234,701
R01 · FY2001 · NS
CLINICAL AND MOLECULAR STUDIES OF GAUCHER DISEASE$28,540
M01 · FY2001 · RR
ENZYME AUGMENTATION THERAPY OF GAUCHER DISEASE$28,540
M01 · FY2001 · RR
GAUCHER DISEASE$318,788
R01 · FY2000 · DK
PROSAPOSINS PHYSIOLOGIC ROLE$258,926
R01 · FY2000 · NS
INBORN ERRORS OF SPHINGOLIPID CATABOLISM$248,228
R01 · FY2000 · NS
ENZYME AUGMENTATION THERAPY OF GAUCHER DISEASE$28,540
M01 · FY2000 · RR
CLINICAL AND MOLECULAR STUDIES OF GAUCHER DISEASE$28,540
M01 · FY2000 · RR